| 0.8132 -0.058 (-6.61%) | 01-22 11:06 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.38 |
1-year : | 1.8 |
| Resists | First : | 1.18 |
Second : | 1.54 |
| Pivot price | 0.76  |
|||
| Supports | First : | 0.61 | Second : | 0.51 |
| MAs | MA(5) : | 0.74 |
MA(20) : | 0.79 |
| MA(100) : | 2.37 |
MA(250) : | 4.5 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 60.2 |
D(3) : | 38.2 |
| RSI | RSI(14): 40 |
|||
| 52-week | High : | 16.31 | Low : | 0.61 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PBM ] has closed below upper band by 17.6%. Bollinger Bands are 83.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.91 - 0.92 | 0.92 - 0.92 |
| Low: | 0.75 - 0.76 | 0.76 - 0.76 |
| Close: | 0.86 - 0.87 | 0.87 - 0.88 |
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Tue, 20 Jan 2026
Psyence Biomedical Ltd. Announces Postponement of Reverse Stock Split Effective Date - Quiver Quantitative
Tue, 20 Jan 2026
Reverse stock split on hold: Psyence BioMed keeps PBM trading - Stock Titan
Wed, 14 Jan 2026
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split - Chartmill
Wed, 14 Jan 2026
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split - Sahm
Mon, 12 Jan 2026
Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity - The Globe and Mail
Fri, 19 Dec 2025
Psychedelic therapy trial for patients with cancer moves forward in Australia - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 6 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 4.9 (%) |
| Held by Institutions | 2.9 (%) |
| Shares Short | 18 (K) |
| Shares Short P.Month | 16 (K) |
| EPS | -389.99 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.34 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -34.5 % |
| Return on Equity (ttm) | -74.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.65 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0.13 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.27 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|